<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Clinical Trials for COVD-19 Anitbody Drug Demonstrates Low Success Rate
Image Overlay - Clinical Trials for COVD-19 Anitbody Drug Demonstrates Low Success Rate

Clinical Trials for COVD-19 Anitbody Drug Demonstrates Low Success Rate

Clinical Trials for COVD-19 Anitbody Drug Demonstrates Low Success Rate

Clinical trials have demonstrated that Eli Lilly’s anti-SARS-CoV-2 drug is unlikely to improve health outcomes. Enrollment in the trial was paused by the NIH paused following a review by an independent data safety monitoring board – there was very little difference between LY-CoV555 and a placebo. Despite this result, the U.S. government has agreed to pay $375 million for 300,000 doses of the drug as the company has noted that it may work better in earlier stage patients. Yourway supports the full scope of the clinical supply chain by combining years of experience, unrivaled responsiveness, and our global network of GMP depots.

Back to Index
Media

Upcoming Events

Clinical Trial Supply East Coast 2022

October 19-20, 2022
King of Prussia, PA, USA

Media

Articles

Helping Sponsors Navigate Complex Ancillary Supply Sourcing Challenges with Integrated Services

Open chat
Come chat with us!
Hello! How can I help you?